EHRA 2024: Late-Breaking Science Video Collection
Published: 22 April 2024
-
Views:
1267 -
Likes:
7
-
Views:
1267 -
Likes:
7
-
Up Next
-
7m 10sPart 1 | Session 7 AI-Enabled Single-Lead ECG Can Unmask Conduction Tissue Disease
-
4m 54sPart 1 | Session 1 Venous Vascular Closure Vs Manual Compression: Style-AF Roland R Tilz
-
4m 3sPart 1 | Session 2 FIH Clinical Series of Conformable "Single Shot" PFA Catheter for PVI Vivek Reddy
-
8m 5sPart 1 | Session 3 Risk of Stroke or Embolism and AF: ARTESiA Substudy William McIntyre
-
2m 53sPart 1 | Session 4 Ablation Strategies for Repeat Procedures in Recurrent AF: ASTRO Boris Schmidt
-
5m 26sPart 1 | Session 5 Non-Vitamin K Antagonist Oral Anticoagulant in AHRE Patients: NOAH Julius Nikorowitsch
Overview
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice.
More from this programme
Part 1
Expert Interviews
Part 2
Highlights
About the episode
EHRA 24 - In this video, investigator, Dr Giulio Falasconi (Humanitas Research Hospital, IT) joins us to discuss the findings from the QDOT-by-LAWT trial. This study included 162 patients with paroxysmal atrial fibrillation not responding to antiarrhythmic drugs. They were retrospectively enrolled and randomized on a 1:1 basis to the QDOT-by-LAWT study group, and the control group.
Findings showed that the QDOT-by-LAWT group received a significantly reduced procedure time, reporting a median procedure time of 40 minutes as compared to 70 minutes in the control group. The results also showed a significant reduction in radiofrequency time, consisting of 6 minutes for the QDOT-by-LAWT arm compared to 25 minutes in the control group. A significant reduction in fluoroscopy time was also observed. It is also important to note significant differences in hospital complication rate.
Interview Questions:
- What is the importance of this study?
- What was the study design and patient population?
- What are the key findings revealed at EHRA 24?
- What are your take-home messages?
- What further study is needed?
Recorded on-site at EHRA in Berlin, 2024.
Comments